Gain Therapeutics, Inc. (GANX) stock
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.11−0.07 (-5.93%)
Close on Nov 18, 2026Market cap $48.44MP/E –Yield –
Gain Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Gain Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $55.18K, down 60.6% year over year. For fiscal 2023 it was $55.18K, down 60.6% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $55.18K | -60.6% |
| FY2022 | Dec 31, 2022 | $140.11K | -15.1% |
| FY2021 | Dec 31, 2021 | $164.99K | +471.3% |
| FY2020 | Dec 31, 2020 | $28.88K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | $0 | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $55.18K | +22.6% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q2 FY2022 | Jun 30, 2022 | $95.10K | +6.6% |
| Q1 FY2022 | Mar 31, 2022 | $45.01K | +754.2% |
| Q4 FY2021 | Dec 31, 2021 | $43.21K | +372.8% |
| Q3 FY2021 | Sep 30, 2021 | $27.35K | +308.4% |
| Q2 FY2021 | Jun 30, 2021 | $89.17K | +1299.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.27K | -21.0% |
| Q4 FY2020 | Dec 31, 2020 | $9.14K | – |
| Q3 FY2020 | Sep 30, 2020 | $6.70K | – |
| Q2 FY2020 | Jun 30, 2020 | $6.37K | – |
| Q1 FY2020 | Mar 31, 2020 | $6.67K | – |
See a number that looks wrong?